Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Glycomimetics’ SEC disclosures can feel like decoding complex carbohydrate chemistry—especially when each 8-K details a new clinical milestone or a Form 4 signals executive confidence in an upcoming sickle-cell trial. If you’ve searched “Glycomimetics SEC filings explained simply,” you’re not alone.
Stock Titan turns that complexity into clarity. Our AI scans every document the moment it hits EDGAR, then delivers plain-English takeaways—so you can grasp efficacy data, financing terms, or partner updates in minutes, not hours. Whether you need the latest “Glycomimetics quarterly earnings report 10-Q filing” or want real-time alerts for “Glycomimetics Form 4 insider transactions real-time,” all the information is gathered and summarized in one place.
Use the platform to:
- Track “Glycomimetics insider trading Form 4 transactions” and spot buying or selling before material events.
- Read a “Glycomimetics annual report 10-K simplified” that highlights R&D spend, cash runway, and pipeline timelines.
- Dig into a “Glycomimetics proxy statement executive compensation” without wading through legalese.
- Stay informed with “Glycomimetics 8-K material events explained,” from trial setbacks to partnership announcements.
- Access concise “Glycomimetics earnings report filing analysis” that connects financials to ongoing studies.
Why it matters: Understanding Glycomimetics’ work on glycomimetic drugs for cancer and sickle cell hinges on knowing when trial phases advance, how much runway cash remains, and what “Glycomimetics executive stock transactions Form 4” reveal about management sentiment. With AI-powered summaries, real-time updates, and historical archives, “understanding Glycomimetics SEC documents with AI” is finally straightforward.
Form 4 filing for GlycoMimetics, Inc. (GLYC) discloses that Fairmount Funds Management LLC, together with affiliated entities (Fairmount Healthcare Fund II L.P., Tomas Kiselak and Peter Harwin), received a grant of 9,023 stock options on 23 Jun 2025. The option has an exercise price of $15.30 and vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, contingent on continued service.
The options are held indirectly by Mr. Harwin for the benefit of investment vehicles managed by Fairmount, which collectively qualify as 10% owners and directors by deputization. Following the grant, the reporting persons own 9,023 derivative securities (no change to non-derivative common share holdings is reported).
No purchase or sale of already-outstanding common shares occurred; the filing represents a routine director compensation award. The size of the grant is immaterial relative to GlycoMimetics’ public float and does not meaningfully affect ownership concentration or potential dilution.
Form 4 highlights: On 06/23/2025, director Alexandra Balcom received a stock option for 9,023 ordinary shares of GlycoMimetics Inc. (ticker indicated as CBIO) at an exercise price of $15.30 per share. The option vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, subject to her continued board service, and expires on 23 Jun 2035.
No other equity transactions—purchases, sales, or additional share ownership—were disclosed. After the grant, Ms. Balcom beneficially owns 9,023 derivative securities directly; Table I for non-derivative holdings is blank, suggesting she held no common shares before the grant.
Implications for investors: The award is part of routine director compensation and does not represent an open-market purchase; therefore, it does not immediately affect the share count or cash flow. The filing adds a modest potential dilution—approximately 9 k shares—once the option is exercised. While small relative to total shares outstanding, the grant aligns the director’s long-term incentives with shareholder value appreciation.
On June 23, 2025, GlycoMimetics, Inc. (GLYC) director David Charles Lubner filed a Form 4 reporting the grant of 9,023 non-qualified stock options at an exercise price of $15.30 per share. The options were acquired for $0.00 and will vest in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, subject to continued board service. They carry a 10-year term, expiring June 23, 2035, and are held directly by the director. No open-market purchases, sales, or dispositions of common shares were reported. The filing represents a routine equity-compensation award and does not convey new information about GlycoMimetics’ operating performance, strategy, or near-term cash flows.
Form 3 overview: On June 23, 2025, officer Ryan Lynch filed an initial statement of beneficial ownership after a multi-step transaction in which GlycoMimetics, Inc. merged with Crescent Biopharma, Inc., adopted the Crescent Biopharma, Inc. name and, on June 16, 2025, redomiciled from Delaware to the Cayman Islands. The filing establishes Lynch’s baseline insider position in the newly constituted issuer (ticker: CBIO).
Equity award details: Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer, reports a stock option for 105,706 ordinary shares at an exercise price of $6.16. The award originated from his pre-merger Crescent option and now entitles him to acquire an identical number of Cayman ordinary shares. Vesting is 25 % on December 27 2025, with the balance vesting in equal monthly instalments through December 27 2028, contingent upon continued service.
Ownership structure and timing: All derivative securities are held directly; no non-derivative share ownership is reported. The Form 3 provides the first Section 16 disclosure for Lynch following the June 13 2025 closing of the merger, allowing investors to track future changes to his stake.
Form 3 highlights a new insider position created by the completion of a complex reverse-merger and redomiciliation involving GlycoMimetics, Inc. (now Crescent Biopharma, Inc.; ticker remains CBIO in the filing header, GLYC in metadata). Richard William Scalzo, recently appointed Chief Financial Officer, has filed his initial statement of beneficial ownership dated 23 June 2025 for an event that occurred on 13 June 2025.
Corporate restructuring. • On 13 June 2025 a two-step merger converted Crescent Biopharma into a wholly owned subsidiary of GlycoMimetics, after which the parent renamed itself Crescent Biopharma, Inc. • On 16 June 2025 the issuer completed a change of domicile from Delaware to the Cayman Islands. All existing equity awards automatically converted into rights over Cayman ordinary shares on a one-for-one basis and under identical terms.
Insider equity. Scalzo reports no non-derivative common shares but holds a single derivative position:
- Stock options: 234,383 ordinary shares, exercise price $9.56.
- Vesting schedule: 25 % on 1 Apr 2026; balance vests monthly until 1 Apr 2029, contingent on continued service.
- Expiration: 1 Apr 2035.
Investor take-away. The filing formally registers the CFO as an insider and discloses his incentive package following the merger and offshore reorganisation. Although no immediate share purchases are shown, the sizable option grant aligns compensation with long-term share performance and signals management continuity post-transaction.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
